The clinical observation that RA patients who had higher baseline bioactive peripheral blood IL-17 levels and were followed for 19.8 years had a higher incidence of stroke, acute myocardial infarction (AMI), or peripheral acute artery ischemia, supports the reported experimental data (75). Here, IL17A is linked to rheumatoid arthritis.